Publication: Progranulin Recruits HSP70 to β-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease
Open/View Files
Date
2016
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Jian, J., Q. Tian, A. Hettinghouse, S. Zhao, H. Liu, J. Wei, G. Grunig, et al. 2016. “Progranulin Recruits HSP70 to β-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease.” EBioMedicine 13 (1): 212-224. doi:10.1016/j.ebiom.2016.10.010. http://dx.doi.org/10.1016/j.ebiom.2016.10.010.
Research Data
Abstract
Gaucher disease (GD), the most common lysosomal storage disease, is caused by mutations in GBA1 encoding of β-glucocerebrosidase (GCase). Recently it was reported that progranulin (PGRN) insufficiency and deficiency associated with GD in human and mice, respectively. However the underlying mechanisms remain unknown. Here we report that PGRN binds directly to GCase and its deficiency results in aggregation of GCase and its receptor LIMP2. Mass spectrometry approaches identified HSP70 as a GCase/LIMP2 complex-associated protein upon stress, with PGRN as an indispensable adaptor. Additionally, 98 amino acids of C-terminal PGRN, referred to as Pcgin, are required and sufficient for the binding to GCase and HSP70. Pcgin effectively ameliorates the disease phenotype in GD patient fibroblasts and animal models. These findings not only demonstrate that PGRN is a co-chaperone of HSP70 and plays an important role in GCase lysosomal localization, but may also provide new therapeutic interventions for lysosomal storage diseases, in particular GD.
Description
Other Available Sources
Keywords
Progranulin, HSP70, β-glucocerebrosidase, Gaucher disease, Lysosomal storage diseases, Pcgin
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service